• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胸腔积液的存在是恶性胸膜间皮瘤患者的一个独立预后因素。

The presence of pleural effusion is an independent prognostic factor in patients with malignant pleural mesothelioma.

作者信息

Wang Haoyu, Yang Ruiyuan, Liu Dan, Li Weimin

机构信息

Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.

State Key Laboratory of Respiratory Health and Multimorbidity, West China Hospital, Chengdu, 610041, Sichuan, China.

出版信息

Sci Rep. 2025 Jan 2;15(1):392. doi: 10.1038/s41598-024-84108-6.

DOI:10.1038/s41598-024-84108-6
PMID:39748018
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11696534/
Abstract

Malignant pleural mesothelioma (MPM) is a rare form of thoracic malignancy with a poor prognosis. Pleural effusion (PE) occurs in the majority of patients with MPM; however, its impact on MPM outcomes remains controversial. We searched for eligible patients from the Surveillance, Epidemiology, and End Results (SEER) database, and clinicopathological information and outcomes were collected. Cox proportional hazard regression analyses were utilized to evaluate the association of PE and other factors with overall survival (OS) and cancer-specific survival (CSS) in patients with MPM. A total of 4185 patients were extracted from the SEER database from 2000 to 2021. The median age of the cohort was 73 years, with a predominance of male patients and epithelioid MPM as the main histological subtype. Univariate Cox regression revealed associations between PE, age, sex, marital status, histology, stage, and treatment with both OS and CSS. Besides, multivariate analyses indicated that PE was independently associated with poorer OS and CSS in patients with MPM, regardless of age, sex, histology, stage, and treatment. Subgroup analyses suggested that PE has a remarkable impact on patients undergoing surgery. PE might serve as an independent prognostic factor in patients with MPM, especially in surgery recipients. Consequently, the development of pleural effusion in these patients should receive increased attention. Future studies are needed to validate these findings, particularly concerning the effect of PE in other clinical settings, such as immunotherapy.

摘要

恶性胸膜间皮瘤(MPM)是一种罕见的胸部恶性肿瘤,预后较差。大多数MPM患者会出现胸腔积液(PE);然而,其对MPM预后的影响仍存在争议。我们从监测、流行病学和最终结果(SEER)数据库中搜索符合条件的患者,并收集临床病理信息和预后情况。采用Cox比例风险回归分析来评估PE和其他因素与MPM患者总生存期(OS)和癌症特异性生存期(CSS)的关联。从2000年到2021年,共从SEER数据库中提取了4185例患者。该队列的中位年龄为73岁,男性患者居多,上皮样MPM为主要组织学亚型。单因素Cox回归显示,PE、年龄、性别、婚姻状况、组织学、分期和治疗与OS和CSS均有关联。此外,多因素分析表明,无论年龄、性别、组织学、分期和治疗情况如何,PE与MPM患者较差的OS和CSS独立相关。亚组分析表明,PE对接受手术的患者有显著影响。PE可能是MPM患者的独立预后因素,尤其是在接受手术的患者中。因此,应更加关注这些患者胸腔积液的发生。需要进一步的研究来验证这些发现,特别是关于PE在其他临床环境中的作用,如免疫治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d76d/11696534/57b72fef0867/41598_2024_84108_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d76d/11696534/ae4eee4afe0e/41598_2024_84108_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d76d/11696534/4df398dfd857/41598_2024_84108_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d76d/11696534/23a396e3359c/41598_2024_84108_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d76d/11696534/57b72fef0867/41598_2024_84108_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d76d/11696534/ae4eee4afe0e/41598_2024_84108_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d76d/11696534/4df398dfd857/41598_2024_84108_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d76d/11696534/23a396e3359c/41598_2024_84108_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d76d/11696534/57b72fef0867/41598_2024_84108_Fig4_HTML.jpg

相似文献

1
The presence of pleural effusion is an independent prognostic factor in patients with malignant pleural mesothelioma.胸腔积液的存在是恶性胸膜间皮瘤患者的一个独立预后因素。
Sci Rep. 2025 Jan 2;15(1):392. doi: 10.1038/s41598-024-84108-6.
2
Determinants of Survival in Malignant Pleural Mesothelioma: A Surveillance, Epidemiology, and End Results (SEER) Study of 14,228 Patients.恶性胸膜间皮瘤生存的决定因素:一项对14228例患者的监测、流行病学及最终结果(SEER)研究
PLoS One. 2015 Dec 14;10(12):e0145039. doi: 10.1371/journal.pone.0145039. eCollection 2015.
3
Assessment of interferon-γ in pleural fluid as a prognostic factor of survival in malignant pleural mesothelioma.胸腔液中干扰素-γ作为恶性胸膜间皮瘤生存预后因素的评估。
Cancer Immunol Immunother. 2021 Nov;70(11):3349-3355. doi: 10.1007/s00262-021-02965-w. Epub 2021 May 18.
4
Impact of surgical intervention on overall survival in malignant pleural mesothelioma: A population-based cohort study with propensity score matching.手术干预对恶性胸膜间皮瘤总生存期的影响:一项基于倾向评分匹配的人群队列研究。
Eur J Surg Oncol. 2025 Jan;51(1):109372. doi: 10.1016/j.ejso.2024.109372. Epub 2024 Nov 7.
5
The Association Between Pleural Fluid Exposure and Survival in Pleural Mesothelioma.胸膜间皮瘤中胸腔液暴露与生存的关系。
Chest. 2021 Nov;160(5):1925-1933. doi: 10.1016/j.chest.2021.05.063. Epub 2021 Jun 11.
6
Malignant pleural mesothelioma: diagnostic value of medical thoracoscopy and long-term prognostic analysis.恶性胸膜间皮瘤:内科胸腔镜的诊断价值及长期预后分析。
BMC Pulm Med. 2018 Apr 3;18(1):56. doi: 10.1186/s12890-018-0619-3.
7
A Nomogram to Predict Prognosis in Malignant Pleural Mesothelioma.预测恶性胸膜间皮瘤预后的列线图
World J Surg. 2018 Jul;42(7):2134-2142. doi: 10.1007/s00268-017-4424-6.
8
Diagnostic value of soluble mesothelin-related peptides in pleural effusion for malignant pleural mesothelioma: An updated meta-analysis.可溶性间皮素相关肽在胸腔积液中对恶性胸膜间皮瘤的诊断价值:一项更新的荟萃分析。
Medicine (Baltimore). 2019 Apr;98(14):e14979. doi: 10.1097/MD.0000000000014979.
9
Gender-based Disparities in Receipt of Care and Survival in Malignant Pleural Mesothelioma.恶性胸膜间皮瘤患者在接受治疗和生存方面的性别差异。
Clin Lung Cancer. 2020 Nov;21(6):e583-e591. doi: 10.1016/j.cllc.2020.05.021. Epub 2020 May 23.
10
Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database.间皮瘤组织学亚型对监测、流行病学和最终结果数据库中预后的影响。
J Surg Res. 2015 Jun 1;196(1):23-32. doi: 10.1016/j.jss.2015.01.043. Epub 2015 Jan 29.

本文引用的文献

1
Leveraging the pleural space for anticancer therapies in pleural mesothelioma.利用胸膜腔进行胸膜间皮瘤的抗癌治疗。
Lancet Respir Med. 2024 Jun;12(6):476-483. doi: 10.1016/S2213-2600(24)00111-5. Epub 2024 May 10.
2
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.2022 年全球癌症统计数据:全球 185 个国家和地区 36 种癌症的发病率和死亡率全球估计数。
CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4.
3
Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study.
帕博利珠单抗联合仑伐替尼二线和三线治疗胸膜间皮瘤患者(PEMMELA):一项单臂 2 期研究。
Lancet Oncol. 2023 Nov;24(11):1219-1228. doi: 10.1016/S1470-2045(23)00446-1. Epub 2023 Oct 13.
4
Meta-Analysis on the Combination of Chemotherapy With Programmed Death-Ligand 1 and Programmed Cell Death Protein 1 Blockade as First-Line Treatment for Unresectable Pleural Mesothelioma.抗 PD-L1/PD-1 单抗联合化疗作为不可切除性胸膜间皮瘤一线治疗的 Meta 分析
J Thorac Oncol. 2024 Jan;19(1):166-172. doi: 10.1016/j.jtho.2023.08.004. Epub 2023 Aug 9.
5
Prognostic impact of pleural effusion in patients with malignancy: A systematic review and meta-analysis.恶性肿瘤患者胸腔积液的预后影响:系统评价和荟萃分析。
Clin Transl Sci. 2022 Jun;15(6):1340-1354. doi: 10.1111/cts.13260. Epub 2022 Mar 21.
6
First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.一线纳武利尤单抗联合伊匹木单抗与化疗治疗不可切除恶性胸膜间皮瘤患者:CheckMate 743研究的3年结果
Ann Oncol. 2022 May;33(5):488-499. doi: 10.1016/j.annonc.2022.01.074. Epub 2022 Feb 3.
7
The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification.《2021年世界卫生组织胸膜肿瘤分类:自2015年分类以来的进展》
J Thorac Oncol. 2022 May;17(5):608-622. doi: 10.1016/j.jtho.2021.12.014. Epub 2022 Jan 10.
8
New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options.恶性胸膜间皮瘤的新纪元:治疗选择的最新进展。
J Clin Oncol. 2022 Feb 20;40(6):681-692. doi: 10.1200/JCO.21.01567. Epub 2022 Jan 5.
9
The Association Between Pleural Fluid Exposure and Survival in Pleural Mesothelioma.胸膜间皮瘤中胸腔液暴露与生存的关系。
Chest. 2021 Nov;160(5):1925-1933. doi: 10.1016/j.chest.2021.05.063. Epub 2021 Jun 11.
10
Addition of radiotherapy to surgery and chemotherapy improves survival in localized malignant pleural mesothelioma: A Surveillance, Epidemiology, and End Results (SEER) study.手术和化疗联合放疗可提高局限性恶性胸膜间皮瘤的生存率:一项监测、流行病学和最终结果(SEER)研究。
Lung Cancer. 2020 Aug;146:120-126. doi: 10.1016/j.lungcan.2020.05.032. Epub 2020 May 30.